Pseudo-Meigs Syndrome: A Case Report
C Papanikolaou, K Fortounis, S Ainalis, K Biba, A Papanikolaou, G Hatzitheoxaris

Citation

Abstract
Meigs syndrome is defined as the co-existence of benign ovarian fibroma, hydrothorax and ascites. On the contrary, Pseudo-Meigs syndrome is characterized by the co-existence of hydrothorax, ascites and other ovarian- usually malignant-or pelvic tumors.

INTRODUCTION
The co-existence of pelvic tumor, hydrothorax and ascites has been known since the late 19th century. The features of the disease were described by Meigs and Cass in 1937. In the same year Roads named it “Meigs syndrome”. Today, Meigs syndrome is defined as the co-existence of benign ovarian fibroma, hydrothorax and ascites. On the contrary, Pseudo-Meigs syndrome is characterized by the co-existence of hydrothorax, ascites and other ovarian- usually malignant- or pelvic tumors. Both these syndromes should be considered in otherwise healthy postmenopausal women, who present with either new or recurrent hydrothorax and ascites. The preoperative differential diagnosis between them is useless, since the surgical resection of the tumor is the only therapeutic choice, resulting to the resolution of fluid accumulations in both situations.

CASE REPORT
A 54 year old postmenopausal woman admitted in our Clinic because of recurrent, since 1 year, perineal phlegmon and currently established respiratory distress.

The clinical examination revealed sinus tachycardia, absence of breath sounds at the auscultation of the right hemithorax, perineal redness and a palpable mass of the lower abdomen. A massive right pleural effusion was found at chest x-ray (Fig. 1).

Figure 1
Figure 1 : Massive fluid effusion of the right pleural cavity

Computed tomography of the abdomen demonstrated mild ascites and a large heterogeneous, with solid and cystic components, pelvic tumor, measured 15x15cm, causing...
pressure to the bladder (Fig. 2A, B).

**Figure 2**
Figure 2A: Mild ascites

**Figure 2B**: Large heterogeneous, with solid and cystic components, pelvic tumor measured 15x15cm and causing pressure to the bladder

These findings were combined with leucocytosis (WBC: 23100/mm³, NE: 87.9%, LY: 7.7%, MO: 3.6%, BA: 0.8%), hyperkalemia (K: 5.9 meq/L) and elevation of tumour markers CEA (5.7ng/ml, NR: <3), CA 19-9 (500U/ml, NR: 0-37) and CA 125 (386.8 U/ml, NR: 0-35).

A preoperative paracentesis and drainage of pleural effusion was necessary to relieve the patient's dyspneic symptomatology. The cytologic examination of the fluid was negative for malignant cells.

The patient underwent an exploratory laparotomy with excision of both the tumor and the right ovary. The tumor was diagnosed histologically as an ovarian well differentiated endometrioid carcinoma (Fig. 3).

**Figure 4**
Figure 3: Papillary and tubular formations of endometrioid carcinoma developed into ovarian substrate (H-E X200)

The immediate postoperative resolution of hydrothorax and ascites confirmed the diagnosis of pseudo-Meigs syndrome (Fig. 4).

**Figure 5**
Figure 4: Resolution of hydrothorax after tumor removal

The patient followed chemotherapy and remains in good condition 18 months after surgery, without any indication of metastatic disease.

**DISCUSSION**
The pseudo-Meigs syndrome can be combined with either benign or malignant neoplasms (Tabl.1).
The etiology of the fluid accumulations remains unclear, although it appears to be related to lymphatic obstruction. The most likely pathogenesis of peritoneal and pleural effusions ascribes filtration of interstitial fluid in the peritoneum through the tumor capsule, and diffusion to the pleural space, usually at the right side, through diaphragmatic lymphatic vessels and apertures, as well as through intercellular gaps and small areas where muscular tissue of the diaphragm is replaced by areolar tissue.

The majority of ovarian tumors, associated with hydrothorax and ascites, have a diameter of more than 6cm. The entity of effusions can be moderate or massive. The effusions generally derive from a transudative process, but can occasionally contain blood cells. Their connection with the pelvic tumor is demonstrated by their regression after neoplasm removal.

The pseudo-Meigs syndrome is clinically important because it resembles metastatic pelvic cancer. Especially in patients with malignant ovarian tumors, cytologic examination of the body cavity effusions is essential to differentiate between reactive process and metastatic tumor spread. While detection of malignant cells is a marker of metastatic disease and a sign of bad prognosis, benign effusions of pseudo-Meigs syndrome affect neither disease stage nor the patient’s prognosis. Determination of the presence or absence of tumor spread is based primarily on cellular morphology study, but if distinction between reactive mesothial and cancer cells is difficult, immunocytochemistry may be necessary.

At this point, must be underlined that an ovarian mass combined with pleural and peritoneal effusions not always represents an advanced malignancy, even with elevation of CA 125 value. There are some benign pelvic lesions causing pseudo-Meigs syndrome, which are associated with elevated levels of this tumor marker, such as struma ovarii, ovarian cystadenomas, uterine leiomyomas and broad ligament leiomyomas. CA 125 levels decline to the normal range after tumor resection.

In the literature, are reported unique, of special interest, cases of pseudo-Meigs syndrome caused by rare pathological conditions (Tabl.2).

CONCLUSION

Pseudo-Meigs syndrome should be considered as a rare differential diagnosis for pleural and ascites effusions. Patients with pseudo-Meigs syndrome may present a diagnostic problem as they masquerade as carcinoma with malignant effusions. Thus they should always undergone exploratory laparotomy. Surgical therapy has a very important role for the complete remission of the disease in
cases of benign tumors, and for the remission of pleural and ascites effusions in cases of malignant tumors.

CORRESPONDENCE TO
Papanikolaou Ch. 28 Sokratous street 55134 Thessaloniki, Greece Tel. 0030 2310 2310 433906 0030 2310 892362 e-mail: ascl@ippokratio.gr

References
Author Information

Ch. Papanikolaou
1st Surgical Clinic, Hippokratio General Hospital

K. Fortounis
1st Surgical Clinic, Hippokratio General Hospital

S. Ainalis
1st Surgical Clinic, Hippokratio General Hospital

K. Biba
1st Surgical Clinic, Hippokratio General Hospital

A. Papanikolaou
Department of Pathology, Hippokratio General Hospital

G. Hatzitheoxaris
1st Surgical Clinic, Hippokratio General Hospital